{"id":898187,"date":"2025-10-21T11:05:20","date_gmt":"2025-10-21T15:05:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/"},"modified":"2025-10-21T11:05:20","modified_gmt":"2025-10-21T15:05:20","slug":"halozyme-to-report-third-quarter-2025-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/","title":{"rendered":"Halozyme to Report Third Quarter 2025 Financial and Operating Results"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced it will release its third quarter 2025 financial and operating results on <span class=\"xn-chron\">Monday, November 3, 2025<\/span>, following the close of trading.<\/p>\n<p>Halozyme will host a conference call on <span class=\"xn-chron\">Monday, November 3, 2025<\/span> at <span class=\"xn-chron\">1:30 p.m. PT<\/span>\/<span class=\"xn-chron\">4:30 p.m. ET<\/span> to discuss the results. The conference call may be accessed live with pre-registration via this link <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4537473-1&amp;h=3316476049&amp;u=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4I78137280&amp;a=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4I78137280\" target=\"_blank\" rel=\"nofollow\">https:\/\/registrations.events\/direct\/Q4I78137280<\/a>.<\/p>\n<p>A live webcast and replay of the conference call will also be available through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4537473-1&amp;h=4138970151&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3775975-1%26h%3D1343769973%26u%3Dhttp%253A%252F%252Fwww.halozyme.com%252F%26a%3Dwww.halozyme.com&amp;a=www.halozyme.com\" target=\"_blank\" rel=\"nofollow\">www.halozyme.com<\/a>.<\/p>\n<p>\n        <b>About Halozyme<\/b>\n      <\/p>\n<p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE\u00ae technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.<\/p>\n<p>Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex\u00ae and XYOSTED\u00ae, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.<\/p>\n<p>Halozyme is headquartered in <span class=\"xn-location\">San Diego, CA<\/span> and has offices in <span class=\"xn-location\">Ewing, NJ<\/span> and <span class=\"xn-location\">Minnetonka, MN.<\/span><span class=\"xn-location\">Minnetonka<\/span> is also the site of its operations facility.<\/p>\n<p>For more information visit <a href=\"http:\/\/www.halozyme.com\" rel=\"nofollow\">www.halozyme.com<\/a> and connect with us on LinkedIn and Twitter.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>Tram Bui<br \/>VP, Investor Relations and Corporate Communications<br \/>609-333-7668<br \/><a href=\"mailto:tbui@halozyme.com\" target=\"_blank\" rel=\"nofollow\">tbui@halozyme.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Sydney Charlton<\/span><br \/>\n        <br \/>Teneo<br \/>917-972-8407<br \/><a href=\"mailto:sydney.charlton@teneo.com\" target=\"_blank\" rel=\"nofollow\">sydney.charlton@teneo.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder6365\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" title=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" alt=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA02850&amp;sd=2025-10-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-report-third-quarter-2025-financial-and-operating-results-302589996.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-report-third-quarter-2025-financial-and-operating-results-302589996.html<\/a><\/p>\n<p>SOURCE  Halozyme Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA02850&amp;Transmission_Id=202510210830PR_NEWS_USPR_____LA02850&amp;DateId=20251021\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Oct. 21, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT\/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https:\/\/registrations.events\/direct\/Q4I78137280. A live webcast and replay of the conference call will also be available through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website at\u00a0www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Halozyme to Report Third Quarter 2025 Financial and Operating Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898187","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Oct. 21, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT\/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https:\/\/registrations.events\/direct\/Q4I78137280. A live webcast and replay of the conference call will also be available through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website at\u00a0www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of &hellip; Continue reading &quot;Halozyme to Report Third Quarter 2025 Financial and Operating Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T15:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Halozyme to Report Third Quarter 2025 Financial and Operating Results\",\"datePublished\":\"2025-10-21T15:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/\",\"name\":\"Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"datePublished\":\"2025-10-21T15:05:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Halozyme to Report Third Quarter 2025 Financial and Operating Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/","og_locale":"en_US","og_type":"article","og_title":"Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Oct. 21, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT\/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https:\/\/registrations.events\/direct\/Q4I78137280. A live webcast and replay of the conference call will also be available through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website at\u00a0www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of &hellip; Continue reading \"Halozyme to Report Third Quarter 2025 Financial and Operating Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-21T15:05:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Halozyme to Report Third Quarter 2025 Financial and Operating Results","datePublished":"2025-10-21T15:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/","name":"Halozyme to Report Third Quarter 2025 Financial and Operating Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","datePublished":"2025-10-21T15:05:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-report-third-quarter-2025-financial-and-operating-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Halozyme to Report Third Quarter 2025 Financial and Operating Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898187"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}